Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?

To: W Shakespeare who wrote (69)	4/20/1999 2:21:00 PM
From: John Metcalf	Read Replies (2) \| Respond to of 101

Feeling lonesome, Will? My reading of the annual report and recent 10-Q is that Akorn needs growth to fully utilize, and pay for, its facilities and staff. To some extent, that growth is restrained by lack of financing. Since the secondary offering was pulled due to market conditions, this issue has been in front of us. On a year-over-year basis, the company has grown through product acquisition. But on a sequential basis, they had a flat quarter. Comments in the annual report about seeking partners to develop new products and use of a product review committee make sense to me. Even though they will have to trade some upside on partnered products, this seems to be the least dilutive avenue available. I anticipate some rebound on partnering news, _if_ and _when_. Thanks, Bard of Akorn -:)